ARCHIVES

MIT’s Sharp To Head Biology Dept.; Hynes To Head Cancer Center

This article is from The Cancer Letter archive.

Vol. 17 No. 15 | April 12, 1991

Download PDF Visit The Full Archive

Related Articles

Aggressive, Tailored Therapy Improves Survival, Study Finds

October 31, 2008

Xeloda-Eloxatin Study Updated; Phase III Trial Interim Analysis

December 27, 2002

Funding opportunities listed.

March 26, 2004

Fermilab Treats 1,000th Patient

August 7, 1981

NCI-Approved Clinical Trials Listed For June 2001

July 27, 2001

FDA says official spoke on own behalf in admonition to The Cancer Letter. Association of Health Care Journalists asks FDA official to rescind her rebuke.

March 18, 2005